open access
The treatment of heterozygous familial hypercholesterolemia — a local perspective
Affiliations- Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
open access
Abstract
none
Abstract
none
Keywords
familial hypercholesterolemia; lipid lowering therapy; PCSK9; alirocumab; evolocumab
About this articleTitle
The treatment of heterozygous familial hypercholesterolemia — a local perspective
Journal
Issue
Article type
Editorial
Pages
189-190
Published online
2021-06-30
Page views
679
Article views/downloads
606
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2021;72(3):189-190.
Keywords
familial hypercholesterolemia
lipid lowering therapy
PCSK9
alirocumab
evolocumab
Authors
Łukasz Bułdak
References (13)- Dyrbuś K, Gąsior M, Desperak P, et al. The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals. Atherosclerosis. 2019; 288: 33–41.
- Haase A, Goldberg AC. Identification of people with heterozygous familial hypercholesterolemia. Curr Opin Lipidol. 2012; 23(4): 282–289.
- Krajowe Centrum Hipercholesterolemii Rodzinnej. http://hipercholesterolemia.com.pl/Kontakt,67 (11.05.2021).
- Bułdak Ł, Marek B, Kajdaniuk D, et al. Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol Pol. 2019; 70(6): 511–519.
- Hennig M, Brandt-Varma A, Wołoszyn-Durkiewicz A, et al. Monitoring the Effects of Hypolipidemic Treatment in Children with Familial Hypercholesterolemia in Poland. Life (Basel). 2020; 10(11).
- Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021 [Epub ahead of print].
- Zygmunt A, Dąbrowski J, Lewiński A. Specialist thyroid package 1 (PS1) in outpatient endocrine care. Endokrynol Pol. 2020; 71(6): 485–496.
- Leczenie inhibitorami PCSK-9 pacjentów z zaburzeniami lipidowymi (ICD-10 E78.01, I21, I22, I25). https://www.gov.pl/attachment/9ad24526-c366-4b32-b4b0-8eb9a62c9d00 (11.05.2021).
- Brandts J, Dharmayat K, Vallejo-Vaz A, et al. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021; 325: 46–56.
- Cordero A, Rodríguez-Mañero M, Fácila L, et al. Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials. J Diabetes Metab Disord. 2020; 19(2): 759–765.
- Okopień B, Bułdak Ł, Bołdys A. Current and future trends in the lipid lowering therapy. Pharmacol Rep. 2016; 68(4): 737–747.
- Banach M, Duell PB, Gotto AM, et al. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020; 5(10): 1124–1135.
- Surma S, Romańczyk M, Filipiak KJ. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiol J. 2021 [Epub ahead of print].
